Roche has received CE approval in the EU for the Contivue® implant with Susvimo®, a new treatment that slowly releases medicine into the eye and only needs to be refilled about twice a year, reducing the need for frequent eye injections. Long-term studies show it can help maintain vision over many years.
- EU CE mark has been attained for the CONTIVUE Port Delivery Platform
- EMA is initiating a review of CONTIVUE with SUSVIMO in neovascular age-related macular degeneration (nAMD).
- New seven-year data from the LADDER study show CONTIVUE with SUSVIMO provides good visual outcomes with stable retinal anatomy over the longer term, with 6-month durability.
Retina International welcomes this important development, which offers hope for reducing treatment burden and protecting sight for the 1.7 million people in the EU affected by nAMD.
You can access further information and read the full press release here.
